Clinical Trial Update: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluates DLBS1425 as neoadjuvant therapy for stage II or III breast cancer, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DLBS1425

Snippet

Sponsor: Dexa Medica Group | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED